Literature DB >> 8835879

Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments.

T Kimura1, T Ono, J Takamatsu, H Yamamoto, K Ikegami, A Kondo, M Hasegawa, Y Ihara, E Miyamoto, T Miyakawa.   

Abstract

It has been reported that many tau sites in neurofibrillary tangles (NFT) are abnormally phosphorylated. We investigated the phosphorylation of tau in the hippocampus of nondemented patients and Alzheimer's disease patients by immunostaining with five site-specific antibodies against phosphorylated tau. In the pretangle stage, tau in neuropil threads was phosphorylated at serines 199, 202 and 409, numbered according to the longest human tau isoform, whereas tau in some neuronal soma was phosphorylated at serines 199, 202, 409 and 422. Tau at the stage of NFT was phosphorylated at serine 396 and threonine 231 in addition to serines 199, 202, 409 and 422. In the advanced stage, tau in ghost tangles was phosphorylated mainly at serine 396. These results suggest that the phosphorylation of each site in tau differs among the maturing stages of neurofibrillary change and that abnormal phosphorylation of tau in the neuronal soma occurs at 199, 202, 409 and 422 earlier than at threonine 231 and serine 396.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8835879     DOI: 10.1159/000106875

Source DB:  PubMed          Journal:  Dementia        ISSN: 1013-7424


  43 in total

1.  Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer's disease.

Authors:  Laurel Vana; Nicholas M Kanaan; Isabella C Ugwu; Joanne Wuu; Elliott J Mufson; Lester I Binder
Journal:  Am J Pathol       Date:  2011-09-23       Impact factor: 4.307

2.  Sensitive quantitative assays for tau and phospho-tau in transgenic mouse models.

Authors:  Christopher M Acker; Stefanie K Forest; Ray Zinkowski; Peter Davies; Cristina d'Abramo
Journal:  Neurobiol Aging       Date:  2012-06-21       Impact factor: 4.673

3.  Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms.

Authors:  Cathy Andorfer; Christopher M Acker; Yvonne Kress; Patrick R Hof; Karen Duff; Peter Davies
Journal:  J Neurosci       Date:  2005-06-01       Impact factor: 6.167

4.  Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport.

Authors:  Chelsea T Tiernan; Benjamin Combs; Kristine Cox; Gerardo Morfini; Scott T Brady; Scott E Counts; Nicholas M Kanaan
Journal:  Exp Neurol       Date:  2016-06-30       Impact factor: 5.330

5.  Tau pathology involves protein phosphatase 2A in parkinsonism-dementia of Guam.

Authors:  Mohammad Arif; Syed Faraz Kazim; Inge Grundke-Iqbal; Ralph M Garruto; Khalid Iqbal
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-06       Impact factor: 11.205

6.  Inhibition of serine palmitoyltransferase reduces Aβ and tau hyperphosphorylation in a murine model: a safe therapeutic strategy for Alzheimer's disease.

Authors:  Hirosha Geekiyanage; Aditi Upadhye; Christina Chan
Journal:  Neurobiol Aging       Date:  2013-03-23       Impact factor: 4.673

7.  Transgenic expression of the amyloid-beta precursor protein-intracellular domain does not induce Alzheimer's Disease-like traits in vivo.

Authors:  Luca Giliberto; Cristina d'Abramo; Christopher Michael Acker; Peter Davies; Luciano D'Adamio
Journal:  PLoS One       Date:  2010-07-16       Impact factor: 3.240

8.  Tau Oligomer Pathology in Nucleus Basalis Neurons During the Progression of Alzheimer Disease.

Authors:  Chelsea T Tiernan; Elliott J Mufson; Nicholas M Kanaan; Scott E Counts
Journal:  J Neuropathol Exp Neurol       Date:  2018-03-01       Impact factor: 3.685

9.  Tau phosphorylation sites work in concert to promote neurotoxicity in vivo.

Authors:  Michelle L Steinhilb; Dora Dias-Santagata; Tudor A Fulga; Daniel L Felch; Mel B Feany
Journal:  Mol Biol Cell       Date:  2007-10-10       Impact factor: 4.138

Review 10.  Tau aggregation and toxicity in tauopathic neurodegenerative diseases.

Authors:  Nicolette S Honson; Jeff Kuret
Journal:  J Alzheimers Dis       Date:  2008-08       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.